According to the Centers for Disease Control and Prevention (CDC), American health programs that deal with multi-drug resistant turberculosis (MDR-TB) have been reporting drug shortages. These shortages have resulted in treatment delays and inadequate treatment regimens for patients. What are acceptable treatment regimens for patients with MDR-TB? How would you address this issue with your patients?
For more information, please visit MedPageToday.